Secondary Prevention of Coronary Heart Disease in Women: A Call to Action
Authors: Andrew P. Miller, Suzanne Oparil
Journal: Annals of Internal Medicine (2003)

Editorials21 January 2003Secondary Prevention of Coronary Heart Disease in Women: A Call to ActionAndrew P. Miller, MD and Suzanne Oparil, MDAndrew P. Miller, MDFrom The University of Alabama at Birmingham; Birmingham, AL 35294-0007Search for more papers by this author and Suzanne Oparil, MDFrom The University of Alabama at Birmingham; Birmingham, AL 35294-0007Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-2-200301210-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail On the basis of extensive mechanistic evidence from in vitro and animal studies and clinical evidence from observational studies, it was predicted that postmenopausal hormone replacement therapy would protect women from coronary heart disease (CHD) events. However, the results of randomized, controlled trials available to date have not supported this prediction (1-3). In fact, the studies have shown evidence of harmincreased CHD events in the first year of treatment and increased stroke and venous thromboembolic events. Although these trials have acknowledged limitations, including use of only a single hormone preparation and participation of older women after many hormone-free years (a ...References1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13. [PMID: 9718051] CrossrefMedlineGoogle Scholar2. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, . Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57. [PMID: 12090862] CrossrefMedlineGoogle Scholar3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized, controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397] CrossrefMedlineGoogle Scholar4. Mosca L, Collins P, Herrington DM, Mendelson ME, Pasternak RC, Robertson RM, . Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499-503. [PMID: 11468217] CrossrefMedlineGoogle Scholar5. 2002 Heart and Stroke Statistical Update. Dallas: American Heart Assoc; 2001. Google Scholar6. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999;341:217-25. [PMID: 10413733] CrossrefMedlineGoogle Scholar7. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7. [PMID: 12365955] CrossrefMedlineGoogle Scholar8. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, . Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-24. [PMID: 9571335] CrossrefMedlineGoogle Scholar9. Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R, . Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-47. [PMID: 11120707] CrossrefMedlineGoogle Scholar10. Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, . Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2003;138:81-9. LinkGoogle Scholar11. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. [PMID: 9603539] CrossrefMedlineGoogle Scholar12. Estelles A, Cano A, Falco , Espana F, Gilabrt J, Grancha S, . Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopauseinfluence of hormone replacement therapy. Thromb Haemost. 1999;81:104-10. [PMID: 10348700] CrossrefMedlineGoogle Scholar13. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, . Subgroup interactions in the Heart and Estrogen/progestin Replacement Study: lessons learned. Circulation. 2002;105:917-22. [PMID: 11864918] CrossrefMedlineGoogle Scholar14. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueria MD, Dracup K, . AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38:1581-3. [PMID: 11691544] CrossrefMedlineGoogle Scholar15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. [PMID: 7968073] MedlineGoogle Scholar16. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22. [PMID: 12114036] CrossrefMedlineGoogle Scholar17. Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, . Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol. 2002;40:693-702. [PMID: 12204499] CrossrefMedlineGoogle Scholar18. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, . Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation. 2002;105:2962-7. [PMID: 12081988] CrossrefMedlineGoogle Scholar19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. [PMID: 11832527] CrossrefMedlineGoogle Scholar20. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, . Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002;288:1882-8. [PMID: 12377087] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From The University of Alabama at Birmingham; Birmingham, AL 35294-0007Corresponding Author: Suzanne Oparil, MD, The University of Alabama at Birmingham, 1034 Zeigler Research Building, 703 19th Street South, Birmingham, AL 35294-0007; e-mail, [email protected]edu.Current Author Addresses: Drs. Miller and Oparil: The University of Alabama at Birmingham, 1034 Zeigler Research Building, 703 19th Street South, Birmingham, AL 35294-0007. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk Factors and Secondary Prevention in Women with Heart Disease: The Heart and Estrogen/progestin Replacement Study Eric Vittinghoff , Michael G. Shlipak , Paul D. Varosy , Curt D. Furberg , Christine C. Ireland , Steven S. Khan , Roger Blumenthal , Elizabeth Barrett-Connor , Stephen Hulley , and Risk Factors and Secondary Prevention in Women with Heart Disease Saif S. Rathore and Harlan M. Krumholz Metrics Cited byThe gender specific frequency of risk factor and CHD diagnoses prior to incident MI: A community studyFallacious Reasoning and Complexity as Root Causes of Clinical InertiaGender Differences in Treatment of Heart Failure and Acute Myocardial InfarctionIdentification of Women's Coronary Heart Disease and Risk Factors Prior to First Myocardial InfarctionHormone Therapy and Selective Estrogen Receptor Modulators for Prevention of Coronary Heart Disease in Postmenopausal WomenRisk Factors and Secondary Prevention in Women with Heart DiseaseSaif S. Rathore, MPH and Harlan M. Krumholz, MDCardiovascular risk in women with type 2 diabetesSex differences in the causes and natural history of heart failure 21 January 2003Volume 138, Issue 2Page: 150-151KeywordsBlood pressureCardiovascular therapyCongenital heart diseaseCoronary heart diseaseEstrogen replacement therapyHazard ratioHypertensionLongitudinal studiesMedical risk factorsMyocardial infarction ePublished: 21 January 2003 Issue Published: 21 January 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...